Project Alzheimer's Value Europe

Recent studies, including a landmark JAMA publication, suggest high-performing blood tests such as C2N Diagnostics PrecivityAD2 could offer a more accessible and accurate way to diagnose #Alzheimers in primary care settings. In PAVE's latest webinar, experts discussed the potential of these tests to revolutionize the diagnostic pathway and reduce delays in timely AD diagnosis. Below, Suzanne Schindler delves deeper into the potential of this approach. Visit our website www.PAVEurope.com to watch the full webinar.

PAVE's latest webinar, "Advancements and Insights in Alzheimer's Research," is now available on our website. This is the first in our Spotlight Series, where we'll be sharing expert insights and the latest research on Alzheimer's disease. The webinar featured Lutz Frölich, Soeren Mattke, and Suzanne Schindler discussing the state of disease research, the importance of early detection, and the potential of blood-based biomarkers. Over the coming weeks, we'll share clips from the presentations. Let us know what you'd like to see more of! https://lnkd.in/eZW_a6Sz #Alzheimersdisease | #AlzheimerResearch | #Healthcare | #EarlyDetection

Last chance to register! Our webinar "Advancements and Insights in Alzheimer's Research" is happening tomorrow, July 10. Lutz Frölich, Soeren Mattke, and Suzanne Schindler will share insights from recently published research and answer questions on healthcare system preparedness for new diagnostics and treatments. Sign up here: https://lnkd.in/eAEvsQTZ

Join us for our upcoming #PAVE Spotlight Series webinar! Learn from leading experts about the latest research on Alzheimer's disease epidemiology and healthcare system preparedness for new diagnostics and treatments. Don't miss this chance to ask questions and be part of the conversation. Date: July 10th, 2024 Time: 10:00 - 11:00 AM EDT / 4:00 - 5:00 PM CEST Location: Online (Zoom) Register here: https://lnkd.in/eAEvsQTZ #AlzheimersDisease | #Healthcare | #HealthSystemPreparedness | #ValueAssessment

At Health Technology Assessment international (HTAi) this week, Jackie Glatter (Alzheimer's Research UK) represented #PAVE on a panel alongside Angela Bradshaw (Alzheimer Europe) and Martina Garau (Office of Health Economics). The virtual session focused on the development of disease-modifying therapies and considerations across the care pathway, from diagnosis to treatment access. Stay connected to PAVE's work on value assessment and access through our website: www.PAVEurope.com

This year's Health Technology Assessment international (HTAi) Annual Meeting in Seville focuses on building global networks for health technology assessment (HTA) and driving innovation through collaboration. PAVE's mission - to address challenges and accelerate solutions related to value assessment of emerging Alzheimer's diagnostics and therapies - aligns with this focus, and we are excited to be part of these important discussions. #HTAi2024 | #Alzheimersdisease | #PAVE | #ValueAssessment

At Alzheimer's Disease International this week, Soeren Mattke presented new research on the preparedness of Germany’s healthcare system to deliver Alzheimer's disease (AD) diagnostic services in preparation for the emergence of a disease-modifying treatment. To support timely access to new treatments, it's crucial to address technological constraints and expand specialist capacity. PAVE is committed to identifying health system solutions to address the growing challenge of AD. Learn more at www.PAVEurope.com.

Methodologies used to assess Alzheimer's disease (AD) diagnostics and therapeutics often fall short of capturing the multifaceted impact of chronic, degenerative conditions such as Alzheimer’s. At Alzheimer Europe 2023, a PAVE-sponsored panel reviewed the need for value assessment frameworks for AD that more effectively capture the patient, care partner, and societal burden of disease. A comprehensive approach considers a wider array of value elements, including qualitative evidence to capture what is deemed important by patients and care partners. Listen to the full discussion and read a follow-up perspective piece from PAVE on our website: https://lnkd.in/e-TmyFBD

PAVE is committed to advancing access to innovations in #Alzheimersdisease diagnostics and therapeutics. We're excited to welcome Daniel Connell and C2N Diagnostics as the newest funder of our work. Learn more at www.PAVEurope.com.

PAVE is proud to welcome C2N Diagnostics as the newest funder of the important work we are doing to address the challenges of Alzheimer's disease therapy and diagnostic value assessment. Learn more by visiting our website at www.PAVEurope.com. #Alzheimersdisease | #PAVE | #ValueAssessment